MedTrace Logo

Extracellular Fluid in Resistant Hypertension

NCT00141596 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2015-06-09

No results posted yet for this study

Summary

The optimal treatment of drug resistant (defined as BP\> 140/85 despite three anti-hypertensive drugs including a diuretic) is not well defined. This study aims to test the hypothesis that resistant hypertension is caused by excessive expansion of extracellular fluid volume. A secondary objective is to study which of three different antihypertensive drugs would be most useful in drug resistant hypertension.

Conditions

Interventions

DRUG

Cardura XL 4 mg bd

DRUG

Amiloride 5 mg bd

DRUG

Furosemide 40 mg bd

Sponsors & Collaborators

  • St George's, University of London

    lead OTHER

Principal Investigators

  • Timothy WR Doulton, BSc MRCP · SGUL

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-07-31
Completion
2006-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00141596 on ClinicalTrials.gov